{"id":12421,"date":"2021-04-23T10:29:41","date_gmt":"2021-04-23T08:29:41","guid":{"rendered":"https:\/\/www.bm-t.de\/?p=12421"},"modified":"2021-04-23T10:29:41","modified_gmt":"2021-04-23T08:29:41","slug":"neurocare-announces-financing-round-with-bmt-and-strategic-investor-apeiron-re-mind","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2021\/neurocare-announces-financing-round-with-bmt-and-strategic-investor-apeiron-re-mind\/","title":{"rendered":"neurocare announces financing round with bm|t and strategic investor Apeiron \/ re.Mind"},"content":{"rendered":"

As another key step towards its planned pub\u00adlic list\u00ading, neu\u00adro\u00adcare is very pleased to announce the clos\u00ading of a sig\u00adnif\u00adi\u00adcant financ\u00ading round with its exist\u00ading anchor investor bm|t and new strate\u00adgic investor re.Mind, the men\u00adtal health fund of Ape\u00adiron, the fam\u00adily office of Chris\u00adt\u00adian Anger\u00admayer, a pro\u00adlific investor in life sci\u00adences and men\u00adtal health, among other sectors.<\/p>\n

neu\u00adro\u00adcare is grate\u00adful to bm|t for par\u00adtic\u00adi\u00adpat\u00ading in this financ\u00ading and believes that re.Mind is a value-enhanc\u00ading strate\u00adgic investor for neu\u00adro\u00adcare. Ape\u00adiron have a proven track record of financ\u00ading inno\u00adva\u00adton in the emerg\u00ading psy\u00adche\u00addelics space. This access to more pschedelics is a com\u00adple\u00adment to neu\u00adro\u00adcare who already col\u00adlab\u00ado\u00adrates with physi\u00adcians apply\u00ading ketamine.<\/p>\n

Kevin Reeder, CEO of bm|t said: \u201cWe are pleased to see neu\u00adro\u00adcare strength\u00aden\u00ading its posi\u00adtion for its much-needed inno\u00adv\u00ada\u00adtive approach in men\u00adtal health, espe\u00adcially once the world is look\u00ading beyond the actual pan\u00addemic to the col\u00adlat\u00aderal dam\u00adage in men\u00adtal health. The endorse\u00adment of a strate\u00adgic investor with such an impres\u00adsive track record is an extremely strong affir\u00adma\u00adtion that neu\u00adro\u00adcare is a best-in-class provider of per\u00adson\u00adal\u00adized men\u00adtal health solutions\u201d.<\/p>\n

Chris\u00adt\u00adian Anger\u00admayer says: \u201cThe con\u00adcept of neu\u00adro\u00adcare rep\u00adre\u00adsents the blue\u00adprint for future men\u00adtal care: they apply a range of strongly evi\u00addenced ther\u00ada\u00adpeu\u00adtics tai\u00adlored to the indi\u00advid\u00adual. Whether it\u2019s neu\u00adro\u00admod\u00adu\u00adla\u00adtion, tra\u00addi\u00adtional CBT or indeed psy\u00adche\u00addelic med\u00adi\u00adcines, neu\u00adro\u00adcare deliv\u00aders world-class per\u00adson\u00adal\u00adized care.\u201d Jan Hardorp, Part\u00adner of re.Mind says, \u201cneu\u00adro\u00adcare has an inno\u00adv\u00ada\u00adtive model of care that can also be out-licensed around the world. They are grow\u00ading rapidly, with a supe\u00adrior eco\u00adnomic model to what we\u2019ve seen else\u00adwhere. We join neu\u00adro\u00adcare so that more patients can access solu\u00adtions befit\u00adting the com\u00adplex nature of men\u00adtal health. We are proud to become an anchor investor in neu\u00adro\u00adcare and drive syn\u00ader\u00adgies with Apeiron\u2019s port\u00adfo\u00adlio of companies.\u201d<\/p>\n

Alex Zobel, neu\u00adro\u00adcare\u2019s CFO and Tom Mechter\u00adsheimer, Founder and CEO of neu\u00adro\u00adcare said: \u201cWe are excited because the strate\u00adgic fit is very good and we can expand our foot\u00adprint for the demand expected post pan\u00addemic. In recent years we have been inte\u00adgrat\u00ading neu\u00adro\u00admod\u00adu\u00adla\u00adtion into best clin\u00adi\u00adcal prac\u00adtice through our DTx plat\u00adform and with our new part\u00adners we will launch more psy\u00adche\u00addelics. This fund\u00ading will allow us to accel\u00ader\u00adate towards the pub\u00adlic mar\u00adkets and global scal\u00ading. We are grate\u00adful to our exist\u00ading investors and wel\u00adcome our new share\u00adhold\u00aders warmly.\u201d<\/p>\n

About neu\u00adro\u00adcare
\n<\/strong>www.neurocaregroup.com<\/a>
\nneu\u00adro\u00adcare is inno\u00advat\u00ading men\u00adtal health and per\u00adfor\u00admance and devel\u00adoped a dig\u00adi\u00adtal ther\u00ada\u00adpeu\u00adtics (DTx) plat\u00adform <\/em>empow\u00ader\u00ading clin\u00adi\u00adcians to deliver best prac\u00adtice. Fol\u00adlow\u00ading a detailed assess\u00adment, clin\u00adi\u00adcians develop per\u00adson\u00adalised ther\u00adapy plans that lead to best evi\u00addence-based out\u00adcomes. neu\u00adro\u00adcare\u2019s objec\u00adtive and mea\u00adsur\u00adable approach is based on our brain\u2019s nat\u00adural abil\u00adity to learn (neu\u00adro\u00adplas\u00adtic\u00adity) adding tech\u00adnol\u00adogy to enhance that learn\u00ading and care deliv\u00adery. Since this approach enables indi\u00advid\u00adu\u00adals to regain their self-reg\u00adu\u00adla\u00adtion it is a sus\u00adtain\u00adable solu\u00adtion with very few side effects not merely symp\u00adtom management.<\/p>\n

About re.Mind and Apeiron
\n<\/strong>re.Mind Cap\u00adi\u00adtal is a ven\u00adture cap\u00adi\u00adtal fund founded by Chris\u00adt\u00adian Anger\u00admayer, together with part\u00adners Jan Hardorp and Max de Vere. Anger\u00admayer is best known for his pio\u00adneer\u00ading invest\u00adments into psy\u00adche\u00addelics, and is a co-founder for Atai Life Sci\u00adences and Com\u00adpass Path\u00adways, which today is listed on the NASDAQ. re.Mind invests into com\u00adpa\u00adnies at any stage, which are cre\u00adat\u00ading rad\u00adi\u00adcal new solu\u00adtions in men\u00adtal health and neu\u00adro\u00adscience. In 2020, Anger\u00admayer was the key dri\u00adver behind IPOs and major fundrais\u00adings of Com\u00adpass Path\u00adways, AbCellerea and Sen\u00adsei Biotherapeutics.<\/p>\n

About bm|t
\n<\/strong>www.bm\u2011t.com<\/a>
\nErfurt-based, beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen (bm|t) \u2014 a sub\u00adsidiary of the Th\u00fcrin\u00adgen Devel\u00adop\u00adment Bank, is a the first address for invest\u00adments in Th\u00fcrin\u00adgen, Ger\u00admany. bm|t cur\u00adrently man\u00adages ten invest\u00adment funds with a total vol\u00adume of 440M EUR. bm|t invests in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies with strong growth poten\u00adtial across all sec\u00adtors and all phases of the cor\u00adpo\u00adrate lifecycle.<\/p>\n","protected":false},"excerpt":{"rendered":"

Neu\u00adro\u00adcare is very pleased to announce the clos\u00ading of a sig\u00adnif\u00adi\u00adcant financ\u00ading round with its exist\u00ading anchor investor bm|t and new strate\u00adgic investor re.Mind, the men\u00adtal health fund of Ape\u00adiron, the fam\u00adily office of Chris\u00adt\u00adian Anger\u00admayer, a pro\u00adlific investor in life sci\u00adences and men\u00adtal health, among other sectors.<\/p>\n","protected":false},"author":2,"featured_media":8438,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[3],"tags":[210,159,176,177],"class_list":["post-12421","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-3","tag-investeepartner","tag-investment-en","tag-bm-t-en","tag-bmt-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/12421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=12421"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/12421\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/8438"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=12421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=12421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=12421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}